Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Samuel Stevens

Has grant

Clinical Senior Lecturer

University of Sydney

Australia

Research Interests

Explore related searches

Professors in Australia

Recent Grants

Grant: Open

RACP Robert and Elizabeth Albert Travel Grant - Common Sense Oncology Fellowship

Open Date: 2026-01-01

Close Date: 2026-12-01

Grant: Close

Evaluating the time toxicity of chemotherapy for metastatic colorectal cancer using patient survey data: a prospective feasibility study

Open Date: 2024-07-01

Close Date: 2026-06-01

Grant: Close

Evaluating the time toxicity of cancer treatments in patients with advanced solid-organ malignancy

Open Date: 2023-12-01

Close Date:

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Collaborators (10)

Manju George

Assistant professor/Chair, Mississippi colorectal cancer Roundtable

University of Mississippi Medical Center

UNITED STATES

View details

Tammy Hoffmann

Bond University

AUSTRALIA

View details

David B Anderson

University of Sydney

AUSTRALIA

View details

Rachel Vogel

Faculty, Associate Professor

University of Minnesota

UNITED STATES

View details

Kirsten J McCaffery

NHMRC Principal Research Fellow

University of Sydney

AUSTRALIA

View details

Raaj Kishore Biswas

Biostatistician

University of Sydney

AUSTRALIA

View details

Arjun Gupta

University of Minnesota

UNITED STATES

View details

Justin Lantz

Associate Professor of Clinical Physical Therapy and Family Medicine

University of Southern California

UNITED STATES

View details

Timothy Boerger

Research Assistant Professor

Marquette University

UNITED STATES

View details

Saroj Niraula

Associate Professor

BC Cancer

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Samuel Stevens

Research Interests

Explore related searches

Recent Grants

Articles (20)

Development and acceptability of a patient decision aid for people with degenerative cervical myelopathy: an international mixed-methods study

Characteristics of cancer drug-indication pairs recommended for funding on the Australian Pharmaceutical Benefits Scheme (PBS), 2005-2025.

Accuracy of patient, care partner, and clinician health care contact day recall.

Patient, care partner, and oncologist perspectives on clinically important survival thresholds after considering time toxicity in advanced cancer

Stakeholder Perspectives on the Term Time Toxicity to Describe Health Care Contact Time Associated With Cancer Treatments

Conflicts of interest and interpretive authority in oncology

Realizing the benefits of tumour-agnostic access requires a national health learning system

Health technology agencies' reimbursement decisions for cancer drugs across four high-income countries.

Tailoring survivorship care for older long-term survivors of breast and colorectal cancer

Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter.

How Important is Healthcare-Contact Time to Systemic Treatment Decision-Making in Advanced Gastrointestinal Cancers: Developing Attributes to Include in a Discrete Choice Experiment

Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer

Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply

CodeBreaK or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer

Overall survival assessment in cancer drug trials: a luxury or a necessity?

Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care

What is the role of common sense oncology in the Western Pacific?

“The Cancer is My Life”: patient and caregiver perceptions of the time toxicity of palliative systemic cancer treatments for advanced gastrointestinal cancers

Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab

Collaborators (10)

Manju George

Tammy Hoffmann

David B Anderson

Rachel Vogel

Kirsten J McCaffery

Raaj Kishore Biswas

Arjun Gupta

Justin Lantz

Timothy Boerger

Saroj Niraula

Make your next move.

Samuel Stevens

Research Interests

Explore related searches

Recent Grants

Articles (20)

Development and acceptability of a patient decision aid for people with degenerative cervical myelopathy: an international mixed-methods study

Characteristics of cancer drug-indication pairs recommended for funding on the Australian Pharmaceutical Benefits Scheme (PBS), 2005-2025.

Accuracy of patient, care partner, and clinician health care contact day recall.

Patient, care partner, and oncologist perspectives on clinically important survival thresholds after considering time toxicity in advanced cancer

Stakeholder Perspectives on the Term Time Toxicity to Describe Health Care Contact Time Associated With Cancer Treatments

Conflicts of interest and interpretive authority in oncology

Realizing the benefits of tumour-agnostic access requires a national health learning system

Health technology agencies' reimbursement decisions for cancer drugs across four high-income countries.

Tailoring survivorship care for older long-term survivors of breast and colorectal cancer

Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter.

How Important is Healthcare-Contact Time to Systemic Treatment Decision-Making in Advanced Gastrointestinal Cancers: Developing Attributes to Include in a Discrete Choice Experiment

Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer

Factors that can make overall survival unreliable as a clinical trial outcome – Authors&apos; reply

CodeBreaK or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer

Overall survival assessment in cancer drug trials: a luxury or a necessity?

Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care

What is the role of common sense oncology in the Western Pacific?

“The Cancer is My Life”: patient and caregiver perceptions of the time toxicity of palliative systemic cancer treatments for advanced gastrointestinal cancers

Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab

Collaborators (10)

Manju George

Tammy Hoffmann

David B Anderson

Rachel Vogel

Kirsten J McCaffery

Raaj Kishore Biswas

Arjun Gupta

Justin Lantz

Timothy Boerger

Saroj Niraula

Make your next move.

Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply